* 中国生物科技公司--科伦博泰生物6990.HK周二早盘低开1.3%后转升最多2.2%。
* 该公司此前公告称，核心产品芦康沙妥珠单抗获国家药品监督管理局批准第二个适应症，用于治疗经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）和含铂化疗治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）成人患者。
* 科伦博泰生物今年迄今大涨50.8%，同期恒生指数.HSI大幅上扬18%。
* 恒生香港上市生物科技指数.HSHKBIO盘中升1.3%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 张喜良)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.